The Uromigos

Ananya Choudhury discussed the evidence for RT/TMT instead of surgery in muscle invasive bladder cancer. Regina Barragan-Carrillo (Golden Ticket Winner) introduces the podcast.

Chana discusses her role at the FDA, how it functions and answers questions on topical issues.

Mat Galski discusses the past, present and future of ctDNA in this disease.

Walt Stadler gives tips to writing papers and navigating the review process.

Laurence Albiges discusses biomarker studies, new combinations and new therapies which were covered in the KCRS23 meeting in the ‘new studies' session.

Rachel Giles (chair of IKCC) describes her data from patients on these topics in RCC

Neeraj Agarwal describes the TALAPRO-2 study and relevance of the HRR biomarker in the 2 cohorts presented. A discussion regarding other PARPis and BRCA1/2 occurs

Meredith Regan and David McDermott try to make sense of it all but are unexpectedly interrupted. PFS2 and TFS are covered along with previously discussed endpoints.

After the discussion with Mike Atkins, Bob Motzer gives his perspective of the 1st line renal cancer situation .

Prompted by a question during the oral kidney cancer session at ASCO, Mike Atkins explains his position. Disagreement prevails.

Silke Gillessen joins Brian and Tom for a quick round up.

Shilpa Gupta discussed these 2 oral abstracts from ASCO

Toni Choueiri describes the results of this renal cancer trial exploring rechallange with immune therapy

Karim Fizazi described the radiotherapy component of this study.

ASCO 2023: TALAPRO-2: Phase 3 Study of Talazoparib + Enzalutamide

yohann Loriot discusses this practice changing trial

Meredith Regan describes how best to interpret KM curves and comparative analysis.

A look forward to bladder, kidney and prostate cancer sessions at ASCO 2023

Nick James describes the success this practice changing multi arm prostate study with an adaptive design

Josh Meeks describes his teams Nature Communications paper (including 11 supplementary figures).

Tom, who failed to invite a guest, quizzes Brian on the new data from the meeting he attended.

Jorge A. Garcia, MD, FACP, chairperson of the Oncologic Drugs Advisory Committee (ODAC) for the US Food & Drug Administration, shared insight on the recent ODAC meeting where members determined that olaparib plus abiraterone as an upfront treatment for mCRPC should be restricted to patients with BRCA mutations. Dr. Garcia is a medical oncologist at the University Hospitals Seidman Cancer Center an...

Daniel Heng, MD, MPH, FRCPC, joins us to discuss IMDC classification for renal cell carcinoma and the treatment of patients with favorable risk disease. Dr. Heng is a professor of oncology at the University of Calgary in Alberta, Canada, and is the leader of the International mRCC Database Consortium (IMDC) which consists of data from over 9,200 patients with mRCC treated with targeted therapies f...

In the first part of our Hollywood tour, Amar Kishan, MD, joins us to discuss his recent meta-analysis published in the Journal of Clinical Oncology on the effects of concurrent adjuvant sequencing versus neoadjuvant concurrent sequencing. Dr. Kishan also gives an overview of the added benefit that androgen deprivation therapy provides when combined with radiation therapy. Dr. Kishan is the Vice C...

Karine Trindade e Fernando Maluf dão uma visão geral da reunião e dos avanços na investigação do câncer no Brasil